Technology & Science
Nov. 3, 2010
Federal Circuit Reviews Gene Patents
The federal government ready to reverse a 30-year precedent allowing patents for genetic material, but supports patents for biotech research methods.
Daily Journal Staff Writer
The federal government stands ready to reverse a 30-year precedent allowing patents for genetic material, but still supports patents for methods that biotechnology companies use to research diseases, drugs and diagnostic tests tied to human genes.
That's the message in an amicus brief filed Friday by the U.S. Department of Justice in Molecular Pathology, et. al. v. the U.S. Patent and Trademar...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In